Gemfibrozil

Contraindicated

Gemfibrozil Simvastatin Flolipid Increased exposure of simvastatin acid (active metabolite) and an increased risk of myopathy or rhabdomyolysis Details Gemfibrozil Daprodustat Jesduvroq Increased daprodustat exposure Details Gemfibrozil Ezetimibe Zetia Increased ezetimibe exposure and an increased risk of cholelithiasis, myopathy and rhabdomyolysis Details Gemfibrozil Ciprofibrate An increased risk of rhabdomyolysis and myoglobinuria Details Gemfibrozil Dasabuvir Increased dasabuvir exposure and an increased risk of QT interval prolongation Details Gemfibrozil Elagolix Orilissa Increased elagolix exposure and an increased risk of elagolix-related adverse reactions Details Gemfibrozil Grazoprevir Increased grazoprevir exposure and an increased risk of ALT elevation Details Gemfibrozil Repaglinide Prandin® Increased plasma concentrations of repaglinide Details Gemfibrozil Selexipag Uptravi Increased selexipag exposure and an increased exposure of its active metabolite Details

Major

Gemfibrozil Colchicine Colcrys An increased risk of myopathy, including rhabdomyolysis Details Gemfibrozil Atogepant Qulipta Increased atogepant exposure Details Gemfibrozil Aztreonam Injection Azactam Increased risk of aztreonam exposure Details Gemfibrozil Atorvastatin Atorvaliq Increased atorvastatin exposure and an increased risk of myopathy or rhabdomyolysis Details Gemfibrozil Baricitinib Olumiant Increased baricitinib exposure Details Gemfibrozil Bexarotene Targretin Increased plasma concentrations of bexarotene Details Gemfibrozil Bexarotene Topical Targretin Increased plasma concentrations of bexarotene Details Gemfibrozil Cyclosporine Injection Atopica Increased risk of renal dysfunction Details Gemfibrozil Cyclosporine Ophthalmic Cequa Increased risk of renal dysfunction Details Gemfibrozil Desloratadine Clarinex Increased desloratadine exposure Details Gemfibrozil Eluxadoline Viberzi Increased eluxadoline exposure Details Gemfibrozil Fluvastatin Lescol An increased risk of myopathy or rhabdomyolysis Details Gemfibrozil Amiodarone Nexterone Increased amiodarone exposure Details Gemfibrozil Apalutamide Erleada Increased apalutamide exposure Details Gemfibrozil Atrasentan Increased atrasentan exposure and an increased risk of atrasentan-related adverse reactions Details Gemfibrozil Aztreonam Increased risk of aztreonam exposure Details Gemfibrozil Cyclosporine Atopica Increased risk of renal dysfunction Details Gemfibrozil Dabrafenib Tafinlar Increased dabrafenib exposure Details Gemfibrozil Enzalutamide Xtandi Increased enzalutamide exposure, an increased risk of enzalutamide-related adverse reactions and an increased risk of seizures Details Gemfibrozil Imatinib Gleevec Increased imatinib trough level or reduced imatinib exposure Details Gemfibrozil Insulin Icodec-Abae Awiqli An increased risk of hypoglycemia Details Gemfibrozil Iptacopan Increased iptacopan exposure and an increased risk of iptacopan-related adverse effects Details Gemfibrozil Irinotecan Camptosar Increased irinotecan exposure and an increased irinotecan active metabolite exposure Details Gemfibrozil Irinotecan Liposome Onivyde Increased irinotecan exposure and an increased irinotecan active metabolite exposure Details Gemfibrozil Loperamide Diamode An increased loperamide exposure and an increased risk of loperamide-related adverse reactions Details Gemfibrozil Lovastatin Altocor® Increased exposure of lovastatin acid (active metabolite) and an increased risk of myopathy or rhabdomyolysis Details Gemfibrozil Momelotinib Ojjaara Increased momelotinib exposure and an increased risk of momelotinib-related adverse reactions Details Gemfibrozil Ozanimod Increased exposure of the active metabolites of ozanimod and an increased risk of ozanimod-related adverse reactions Details Gemfibrozil Paclitaxel Abraxane Increased PACLitaxel exposure Details Gemfibrozil Paclitaxel Protein-Bound Increased PACLitaxel exposure Details Gemfibrozil Pioglitazone Actos Increased pioglitazone exposure Details